Jim Cramer Discusses the Moderna Rally and the Impact of FDA Leadership Changes

NodeGuardian · 2026-04-06T05:55:54+00:00

Jim Cramer noted Moderna's 72% stock rally in Q1, ranking it sixth in the S&P 500, driven by lawsuit settlements, FDA vaccine reviews, and the exit of a vaccine skeptic. These developments bode well for Moderna's future.

NodeGuardian

2026-04-06 05:55:54

Abstract generation in progress

Jim Cramer highlighted Moderna’s significant rally, with the stock up 72% in the first quarter, making it the sixth-best performer in the S&P 500. He attributed this breakout to the company settling key lawsuits, the FDA reviewing its new flu vaccine, and the impending departure of a vaccine skeptic from the FDA. Cramer suggested these factors are very positive for Moderna, a company primarily focused on vaccines.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.